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Summary Seventy-one patients with poor-prognosis breast cancer were enrolled after informed consent in a multicentre randomized study
to evaluate the use of selected peripheral blood CD34- cells to support haematopoietic recovery following high-dose chemotherapy. Patients
who responded to conventional chemotherapy were mobilized with chemotherapy (mainly high-dose cyclophosphamide) and/or recombinant
human granulocyte colony-stimulating factor (rhG-CSF). Patients who reached the threshold of 20 CD34- cells per (l of peripheral blood
underwent apheresis and were randomized at that time to receive either unmanipulated mobilized blood cells or selected CD34- cells. For
patients in the study arm, CD34- cells were selected from aphereses using the lsolex®380 device. Fifteen patients failed to mobilize
peripheral blood progenitors and nine other patients were excluded for various reasons. Forty-seven eligible patients were randomized into
two comparable groups. CD34- cells were selected from aphereses in the study group. Haematopoietic recovery occurred at similar times in
both groups. No side-effect related to the infusion of selected cells was observed. The frequency of epithelial tumour cells in aphereses was
low (8 out of 42 evaluated patients), as determined by immunocytochemistry. We conclude that selected CD34- cells safely support
haematopoietic recovery following high-dose chemotherapy in patients with poor-prognosis breast cancer.
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Breast cancer is the most common malignancx affectinu women in
developed countries. Treatment efficacy and survix al depend on a
number of factors. Ads anced breast cancer essentiallv remains an
incurable disease. Combined surgerv. radiotherapy and consven-
tional chemotherapx regimens produce only 5-25%7 complete
remissions and a median sun-is-al of 5-13 months in patients with
metastatic breast cancer (Harris et al. 1997). There is an increasing,
interest in hiah-dose chemotherapy for patients with adxanced
breast cancer. Although definitive answers will axx-ait termination
and anail-sis of large randomized European and North American
trials. there are indications that increasinc the dose intensitx mav
contribute to a better outcome. at least for some subsets ofpatients
with breast cancer (Bonadonna and Valagussa. 1981: Tannock et
al. 1988: Dunphy et al. 1990: Wallerstein et al. 1990: Engelsman et
al. 1991: Kennedx et al. 1991: Antman et al. 1992: Peters et al.
1993: Wood et al. 1994: Besswoda et al. 1996).
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Within the last fess Xears. autologous mobilized peripheral
blood cells have been substituted for autolocous bone marrow. to
pros ide haematopoietic support after high-dose chemotherapy for
a varietv of maliLnancies. includincz breast cancer (Gale et al.
1993: Gratwohl et al. 1996). Mobilized peripheral blood cells
pros'ide more rapid recoxen- of neutrophils and platelets than
bone marrow after high-dose chemotherapy. thus reducing the
morbidity. the use of medical resources and the cost of transplant
procedures (Faucher et al. 1994: Hartmann et al. 1996: Schmitz
et al. 1996: To et al. 1997). Howesver. unmanipulated aphereses
contain onlv a small proportion of progenitors. along w-ith subsets
of differentiated and accessonr cells. and. in some cases. tumour
cells (Ross et al. 1993: Brugaer et al. 1994a): the latter appear to
be mobilized bv chemotherapy and haematopoietic grosth factors
to some extent (Brugger et al. 1994a). Because aene markinu
studies suggest that residual tumour cells in the graft may
contribute to relapses occurring in a proportion of patients A-ith
other malignancies (Brenner et al. 1993: Deisseroth et al. 1994).
there is an incentisve to separate progenitors from other unneces-
sary cells present in the initial collection (Kennedv et al. 1991:
Shpall et al. 1991a. b). Human haematopoietic progenitors express
the CD34- antigen (Andresws et al. 1992: Link et al. 1996:
Bensinger et al. 1997). a sialomucin of unknosn function (He et
al. 1992: Simmons et al. 1992: Baumhueter et al. 19931. There is
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no clear demonstration so far that breast cancer cells express
CD34. Therefore. selection of CD34+ cells may reduce or elimi-
nate contaminating tumour cells from the graft. In addition to this
purging' effect. CD34+ cell selection yields a well-characterized
cell population - therefore producing a unique setting to study the
relation between the number of infused progenitors and the
haematopoietic recovery. Fmally. selection ofCD34+ cells leads to
cryopreservation of small numbers of cells in a small volume.
containing a small amount of cryoprotective agent and may thus
reduce both storage costs and side-effects associated with reinfu-
sion of these cryoprotective agents such as dimethylsulphoxide
(DMSO) (Shpall et al, 1997).
Engraftnent after infusion ofautologous selected CD34+ cells -
either from bone marrow or mobilized blood cells - has alrady
been reported (Berenson et al. 1991: Brugger et al, 1994b: Shpall
et al, 1994: Gorin et al. 1995: Schiller et al. 1995: Civin et al.
1996; Lemoli et al. 1996: Mahe et al, 1996: Williams et al, 1996:
Hohaus et al, 1997: Lopez et al, 1997; Mapara et al, 1997; Marin et
al, 1997: McQuaker et al. 1997: Somlo et al, 1997). These studies
- including patients with breast cancer - demonstrated that
haematopoietic recovery occurred after infusion ofselected CD34+
cells. However, with one exception (Shpall et al. 1997). a study
based on the reinfusion of bone marrow cells, comparison with
historical controls did not allow forthe assessment ofthe influence
of the selection process on the speed and durability of haemato-
poietic recovery, or of the incidence of side-effects. The present
randomized multicentre study was designed to assess the safety
and efficacy of using autologous selected CD34+ cells to support
haematopoietic recovery following high-dose chemotherapy in
patients with poor-prognosis breast cancer.
PATIENTS AND METHODS
Patients
From November 1994 to December 1995. 71 patients entered a
randomized multicentre study designed to evaluate the safety and
efficacy ofselected peripheral blood CD34+ cells, to support autol-
ogous haematopoietic recovery after high-dose chemotherapy for
poor-prognosis breast cancer. All patients had histologically docu-
mented adenocarcinoma of the breast: patients were considered to
be at high-risk because they had metastatic disease, or because they
had more than eight positive nodes. and were thus eligible for insti-
tutional protocols using dose-intensified chemotherapy with
haematopoietic cell support. The study was reviewed and approved
by the Comite Consultatif de Protection des Personnes dans la
Recherche Biomedicale (CCPPRB) in Marseilles. for French
centres. and by Institutional Review Boards at US institutions. All
patients gave informed consent before entering the study. All
patients were assigned a study number, but were not randomized
until time of successful mobilization, as defined below.
Collection of peripheral blood stem cells (PBSCs)
Peripheral blood progenitors were mobilized with a variety of
regimens, according to institutional protocols: in most cases, it
included high-dose cyclophosphamide (see Table 1). followed by
the daily administration of recombinant human granulocyte
colony-stimulating factor (rhG-CSF) (Neupogen. Amgen.
Thousand Oaks. CA. USA) 5-10 jig kg-' or 300 jg subcutaneous.
until collection of mobilized blood cells. At Indiana University.
patients were mobilized with rhG-CSF alone (10gog kg-' day-').
Because a variety of mobilization regimens were used. a standard
criteria for successful mobilization was established: apheresis was
started when the absolute number of CD34+ cells in the peripheral
blood rose above 20gl.-' Patients who failed to reach this
threshold were excluded. Patients who successfully mobilized
were randomized at that time to the control arm or the test arm.
using a computer-generated random assignment list for each
participating medical centre. Randomized patients were further
analysed on an intent-to-treat basis. unless otherwise indicated.
Aphereses were performed with an automated processor
(CS3000®. Baxter-Fenwal Division. Deerfield. IL, USA. or Cobe
Spectra®. Lakewood, CO. USA), and approximately two blood
volumes were processed during each 3- to 4-h session. Aphereses
were repeated on a daily basis until the equivalent of at least
2.5 x 106 CD34+ cells kg-' were collected for patients in the control
arm. and at least 6.5 x 106 CD34+ cells kg-' were collected for
patients in the study arm (of whichS x 106 CD34+ cells kg-' were
used forcell separation and 1.5 x 106 CD34+ cells kg-' were cryop-
reserved unmanipulated as aback-up). Patients who failed to reach
these thresholds were removed from the study. These figures were
based on reports that were available at initiation of the study.
regarding the minimal number ofCD34+ cells that ensures optimal
engrafment (Bender et al, 1992; Bensinger et al. 1994: Haas et al.
1994; van de Wall et al, 1994; Faucher et al. 1996). and on the
assumption that the yield ofthe cell separation procedure would be
approximately 50%, thus providing for similar numbers ofprogen-
itors in both groups.
Selection of CD34+ cells
CD34+ cells were separated from apheresis products. using the
Isolex®300 device according to the manufacturer's instructions.
with chymopapain as an agent to release immunomagnetic beads
from target cells (Civin et al. 1996; Hohaus et al. 1997; Mapara et
al. 1997). When CD34+ cells had to be separated on the day
following apheresis, cells were stored overnight at 4°C or at room
temperature. In brief, the cells were centrifuged at low speed to
deplete platelets, and washed once with a buffer solution
containing 1% (v/v) human serum albumin. The volume was
adjusted to 100 ml. and 0.5 g of human immunoglobulin was
added. Clinical grade murine class H anti-CD34 antibody (9C5)
was also added to a final concentration of 0.5 jg 10-6 nucleated
cells. After a 15-min incubation, the cells were washed once with a
buffer solution, and transferred to the Isolex® disposable chamber,
and the volume adjusted to 300 ml. An additional 0.5 g of human
immunoglobulin and one vial ofprewashed sheep anti-mouse IgG-
coated paramagnetic beads (Dynabeads® M-450. Dynal) was
added to the chamber. Following 30 min of incubation, the non-
target (CD34 'minus') cells were drained from the chamber, and
the target CD34+ cell-bead complexes were washed three times
with a buffer solution. The cells were released from the beads by
the addition of 8000 pkat clinical grade chymopapain (Chymo-
Cell-T). which cleaves a chymopapain-sensitive epitope recog-
nized by the 9C5 monoclonal antibody on the CD34 molecule
(Greaves et al. 1995). followed by a 15-min incubation. The
CD34+ cells - free of beads - were drained from the chamber and
washed before cryopreservation.
Selected and unselected cell products were cryopreserved
according to institutional procedures with 10% DMSO. using
controlled ratefreezing. with the exception ofTexas Oncology PA in
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Table 1 Patient care and accrual
Centre Mobilization Conditioning regimen Patients
Marseille Institut Cyclophosphamide 4 g m-2 Cyclophosphamide 120 mg kg-' 27
Paoli-Calmettes Doxorubicn 75 mg m-2 Mitoxantrone 36 mg m-2
rhG-CSF 300 ,ig day- Melphalan 140 mg/m-2
Indianapolis. Indiana rhG-CSF 10 ug kg-' Cyclophosphamide 6 g m-2 24
University Medical Carboplatin 2 g m-2
Center Etoposide 625 mg m-2
Pans. Hopital Tenon Cyclophosphamide 3 g m-2 Cyclophosphamide 120 mg kg-' 6
Epirubicin 100 mg m-2 Mitoxantrone 45 rng m-
rhG-CSF 300 ,ug day- Melphalan 140 mg rTr2
Dallas. Texas Cyclophosphamide 4 g m-2 Cyclophosphamide 6 g m-2 7
Oncology PA rhG-CSF 5 gg kg-' day- Thiotepa 500 mg m-2
Carboplatin 800 mg m-2
New Haven. Yale Cyclophosphamide 5 g m-2 Thiotepa 900 mg m-2 5a
Universrty rhG-CSF 5 ug kg-' day-
Richmond. Virginia Ifosfamide 4 g m-2 Cyclophosphamide 6 g m-2 2
Commonwealth Cisplatin 50 mg m-2 Thiotepa 500 mg m-2
Unrversity Etoposide 500 mg m-2 Carboplatin 800 mg m-2
rhG-CSF 5 jig kg-' day-'
Total 71
aPatients accrued at Yale were included in a double transplant programme (cycle 1 induded melphalan 140 mg nr2: see Patients and methods). Because a
majority of patients was accrued at two of the six particlpating centres, 65% of the patients actualty received one of two conditioning regimens
(cycophosphamide. melphalan and mitoxantrone, or cyclophosphamide. carboplatin and etoposide)
Dallas (this centre contributed seven patients: Table I). where a
pentastarch cryopreservation solution and dump freezing were used.
The percentages ofCD34- cells and other cell subsets were esti-
mated before and after the separation. using, immunofluorescence
and flow cvtometrv. according to institutional protocols. HPCA-2
(Becton Dickinson. San Jose. CA. USA). a class III anti-CD34
monoclonal antibodv that recognizes a chymopapain-resistant
epitope (Greaves et al. 1995) was used to measure the percentage
of CD34" cells. In order to assess the institutional variation in
analvsis of cell products for content of CD34- cells. available
immunofluorescence data from each site were provided on disks
(no cell sample w-as sent) to a central lab (Hematologics. Seattle.
W'A. USA) for reanalxsis. The percentage ofCD34+ cells reported
from the sites was compared with the percentage of CD34- cells
reported by the central analysis lab. There Aas no difference
between the central lab and the individual labs as a group. when
examining, the percentage of CD34+ cells collected in apheresis
products or in the CD34- cell selection products. When compared
individuall1 with the central lab. only one group appeared to
proxide significantl1 different results (P = 0.034) for the
percentage ofCD34- cells in apheresis products. and the difference
was estimated to be 0.04% (although this difference was statisti-
cally significant. it appears to be clinicallv meaningless). The
comparison of CD34- cell numerations from different centres
gives information on how similarly investigators interpreted flow
cvtometrv data at different workplaces: it does not gixe informa-
tion on how similarly they stain cells and acquire flow cvtometrv
data. However. by demonstrating that all participatina centres
interpretated flow cytometrx data xerv similarly. this is a aood
indication that all steps necessary for CD34- cell measurements
were probablv performed in a similar manner. The percentage ofB
and T cells in cell products x-as also estimated. wvith monoclonal
antibodies recognizing CD19 and CD3 respectively.
Tumour cell contamination
The presence of epithelial tumour cells in aphereses and after
CD34- cell selection w-as independently assessed for all centres at
BIS Laboratories (Reseda. CA. USA) (Moss and Ross. 1992: Ross
et al. 1993). using cryopreserxed cell samples that were collected
at and sent from each participating institution. Cy'tospin slides
were prepared. and at least 106 cells w-ere examined. Tumour cells
wvere detected and quantified usinr immunocytochemistrV
(APAAP). and a combination of five different monoclonal anti-
bodies: IgGI antibodies 9184. 9187 and 9189 (Baxter Healthcare
Corporation) recognize 200-kDa (c-erb2). 55-kDa and 42-kDa
glycoproteins. respectively. w-hich are specifically expressed on
epithelial cells (Ross et al. 1993): SB3 (BIS Laboratories) recog-
nizes 8-. 18- and 19-kDa cvtokeratins and TFS-2 recognizes a
cellular adhesion molecule. A breast cancer cell line w'as used as a
positix e control.
Transplantation
Patients received a varietv ofconditioning regimens. most ofthem
containing alkylatingy agents (Frei et al. 1989) and anthracyclines.
according, to institutional protocols (Table 1). At least 24 h after
completion of the chemotherapy. patients received either cryopre-
served unseparated autologous mobilized blood cells or cryopre-
serxed selected CD34+ cells that were thawed at the bedside.
immediatelv before infusion. Patients receixed rhG-CSF. 5 jig kg-
or 300 jgc daily, starting at day 1 following transplantation. until
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Table 2 Patient charactenstics in non-randomized and treatment groups
(for five patients accrued at Yale University Hospital, collecion was planned
for two transplants)
Non-randomized Control Test
(n=24) (n=21) (n=26)
Median age (years) 48 46 44.5
Range 34-64 31-62 28-0
Stage
11/111 5 6 6
IV 21 12 14
Metastatic sites
Soft tissues 15 3 4
Bone 10 10 10
Marrow 1 2 3
Vlsceral' 9 9 10
Morethan one site 8 6 8
No. of previous regimens
1-2 50.0O 57.20o 69.20o
3 22.70o 33.30o 15.400
> 4 27.30o 9.50o 15.40o
Prior radiotherapy
None 16 11 10
Local 3 10 16
Mobilization regimens 590% 2900 270c
(No. of rhG-CSF/no. of (13/8) (6J15) (7/19)
chemo + rhG-CSF)
No. of aphereses NA 2.2 3.2
(1-6) (2-5)
neutrophil recoxery (ANC > 0.5 x 10 1-' for at least 2 consecutixe
davs). Supportixe care (transfusions. antibiotics. etc.) xxas
provided accordinu to institutional protocols.
Assay for human anti-mouse antibodies (HAMA) and
human anti-sheep antibodies (HASA)
To test for HAMA. the test sxvstem was an ELISA assav for human
antibody to murine IgG using the ImmuSTRIP® HAMA IgG test
(Immunomedics. Warren. NJ. USA). There is neither a reference
method nor reference material for HAMA testing: therefore a
known amount ofstandard x as added to human serum. The differ-
ence betxeen the HAMA concentration before and after 'spiking'
was expressed as a per cent recovery ofthe amount added. Patient
results were reported as falling into one of the followingy three
categories: negatixe (< 74ng, ml-'). positixe (74-440n ml-') or
strongly positive (>440 ng ml-').
A similar ELISA assay x-as used to determine whether HASA
was present. A ratio R xas established between the sample and a
normal control. The samples were scored as follows: ifthe sample
was 1.0 < R < 2.5. the sample was considered negative: if 2.5 < R
< 7.5. the sample was considered positixe: 7.5 < R < 10.0xxas clas-
sified as double positive: 10.0 < R < 20.0 was classified as triple
positive.
Statistical analyses
Statistical analy ses were carried out. using the SAS statistical soft-
ware package. All statistical tests were two-sided. and a signifi-
cance level of 0.05 xxas used tojudge statistically sianificant test
Table 3 Device performance summary and cell product charactenstics
Control Test
Range (n) Median Range (n) Median
Apheresis product
Total nucleated cells (x 109) 2.2-99 4 (44) 12 1 1.4-50 3 (79) 18.4
°O CD34- cells 0.1-11.38 (47) 0.78 0.2-9.1 (81) 0.72
Vkability 90-100 (45) 99 90-100 (77) 99
Isolex! selectedproduct
Total nucleated cells (x 109) NA NA 0.02-0.95 (48) 0.07
'O CD34- cells NA NA 55-99 (48) 89
°O Viability NA NA 84-100 (48) 99
Yield CD34- cells (%O) NA NA 16-170 (48) 44
Log depletion CD3- cells NA NA 2.2-4.6 (29) 3.5
Log depletion CD19- cells NA NA 1.0-3.0 (21) 2.3
results. The primary efficacy objectixe was to determine whether
infusion ofCD34- cells isolated from mobilized blood cells results
in anx delav of neutrophil engraftment (delaV being defined as
more than 3 days). relative to neutrophil engraftment following
transplant w-ith unselected mobilized blood cells. Kaplan-Meier
estimates of time to neutrophil recoxerx were calculated for the
control group (unselected mobilized blood cells) and the test aroup
(selected CD34+ mobilized blood cells). and the log-rank test was
used to assess treatment differences. A sample size of 20 patients
per treatment arm proxides 81.5%-/c power to detect a3-dax differ-
ence in median time to neutrophil engraftment. with a level of
significance of0.056. Secondary engraftment parameters included
time to neutrophils above 1 x I091-. and times to platelets above
20x 1091-l. .Ox 101-Iand lOOx 1091-1.
The primary safety objectixe wxas to determine w-hether infusion
of CD34+ isolated from mobilized blood cells results in any
unusual or unexpected toxic side-effect oxer those observed after
infusion of unselected mobilized blood cells. The incidence of
serious and unexpected side-effects wxas calculated for each treat-
ment group. and Fisher's exact test used to assess treatment differ-
ences. The incidence of infectious episodes with or w-ithout
documentation (culture) was calculated for each treatment group.
Secondarv safety parameters included days of hospitalization
following chemotherapy. days of antibiotic usage and number of
transfusions required for each group.
RESULTS
Patient characteristics and blood cell mobilization
A total of 71 patients were entered in the study from Noxember
1994 to December 1995. at six different medical centres. usinc the
Isolex9300 device to separate CD34+ cells from aphereses. Of the
71. 24 patients were not randomized. 15 because they failed to
meet the mobilization criteria (the number of circulating CD34-
cells did not reach 20 t1'). and nine because ofa varietx ofevents
(two patients had progressive disease. three patients had medical
complications before randomization. one patient was assirned a
number in error. one patient xoluntarilv withdrew from the studv
before randomization and two patients were not monitored for
mobilization). The other 47 patients reached the threshold of 20
CD34+ cells pA-' ofcirculating blood. and were randomly assigned
either to the test group (n = '6). or to the control group (n = 21).
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Table 4 Engraftment summary in the control and test groups
CD34+ cell doe ANC > 500 ml-' ANC> 1000 ml-' Platelet Platelets Platelets
(x 10 kg)-' (days) (days) > 20 000 m1- > 50 000 m-' > 100 000 Mt-
(days) (days) (days)
Range Median Range Median Range Median Range Median Range Median Range Median
Control n=21 2.7-40.1 4.4 8-14 10.0 8-21 11 6-60 10.0 8-88 14.0 10-198 20
Testn=26 0.8-16.0 2.7 9-15 11.0 9-19 12 8-40 12.0 11-40 17.5 14-174 28
Test subseta (n = 21) 0.8-16.0 2.3 9-14 11.0 9-14 12 9-40 12.0 13-40 17.0 14-83 28
-Patients in the test group who did not receive a back-up.
Followinc randomization. ten additional patients did not complete
the studN, as initially planned. for reasons includinc unsatisfactory,
apheresis collections. voluntary withdrawal and death. However.
the analysis was carried out on an intent-to-treat basis. and
includes these patients. except where indicated.
Tables I and 2 describe characteristics of non-randomized and
randomized patients. There was a slight but not significant excess
of patients who had received three or more chemotherapy regi-
mens before studv inclusion in the non-randomized group. There
was also an excess of patients swho were mobilized with rhG-CSF
alone in this group. The control and test groups were comparable
in terms ofstaging. sites ofmetastases. prior treatments (including
chemotherapy. hormone therapy. radiation therapy and surgers)
and centre of origin. It is noticeable that. whereas 43.5%7c of the
patients had bone metastases. only 10.1%7c had documented marrow-
involvement.
Cell selection: progenitor cell recovery and tumour
purging
Table 3 shows the characteristics of collected products in both
groups. Following selection with the Isolex®300 device. the median
recovenr ofCD34 cells was 44%7c. and the median purity ofCD34-
cells was 89%7c. The selection resulted in a final product that
contained a median number of75 x 106 nucleated cells. representing
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Table 5 Patients and products tested for the presence of breast tumour
cells by BIS Laboratories using immunocytochemistry (see Patients and
methods)
Selcted CD34 Unselcted PBSCs
No. of patients tested 24 18
No. negative 19 15
No. of positive apheresis products 5 3
No. of positive CD34 products 2 NA
No. of CD34 products ND or NE 3 NA
ND. not done; NE, not evaluable.
agreaterthan 100-fold reduction from the starting numberofcells in
the apheresis product Despite the fact that many patients had two or
more separations. the number of CD34+ cells that were cryopre-
served for patients in the test group was 2.7 x 106 CD34+ cells kg-'
(2.3 x 106 CD34+ cells kg-' in the subset of patients who did not
receive a back-up). a value that is significantly lowser than for the
control group (4.4 x 106 CD34+ cells kg-': P = 0.0024: Table 4).
Table 5 describes the detection of epithelial tumour cells in
aphereses. The overall frequency of positive products was 12 out
of 84 aphereses. or 14.3%7c. and 8 out of42 tested patients. or 19%.
In positive aphereses. the frequency ofepithelial cells ranged from
I in 2 x 106 to 3 in 1I0 cells. In 5 out of the 8 positive patients.
B
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Figure 1 A Kaplan-Meser analy of time to ANC recovery (ANC >0.5 x 109 -)-
(-. control group: - - -. test group)
B Kaplan-Meser anaysis of timne to platelet recovery (platelets > 20 x 109 I-')
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Table 6 Descrption of clinical events and transfusion requirements in the control group and the test group
Corol Test P
Variable n Mean Range n Mean Range
Random donor platelet units 21 4.2 0-28 26 2.7 0-35 0.4513
Single donor platelet units 21 4.4 0-18 26 4.0 0-29 0.8733
RBC units 21 5.10 2-18 26 5.54 2-25 0.6704
Days in hospital 20 25.9 17-100 26 23.0 11-48 0.5598
Table 7 Distribution of infectious episodes
Infectious disease
No Yes
n % n %
Control group 9 42.86 12 57.14
Test group 12 46.15 14 53.85
Total 21 44.68 26 55.32
consecutixe aphereses w-ere not all positixve. Fixe patients in the
study group had positixe aphereses. but only t%vo of these had
adequate samples for assay of the CD34- cell product. and there-
fore offered an opportunitv to assess the results of CD34- cell
selection in terms of tumour purging: in both cases. immunocy-to-
chemistry still rexealed the presence ofepithelial cells in the final
product. with a frequency of 1-2 in I0W cells. Because the number
of positixely stained cells reported for each sample is so small.
onlv rough calculations oflog tumour cell reductions can be made.
taking into account the reduction in the absolute number ofcells in
the final product: this resulted in an approximately 2.5 log
decrease in the number of tumour cells that were reinfused to the
patient. when compared xwith unseparated PBSCs. Based on the
total number of nucleated cells in the final selected product. this
represents the reinfusion of 100 to 1000 tumour cells in patients in
the test group. who were positixve before selection.
CD34- cell selection also resulted in a decrease in other non-
target cell populations. including T lymphocytes (CD3- cells. 3.5
logs) and B lvmphocytes (CD19- cells. 2.3 logs).
High-dose chemotherapy and engraftment
Patients receixed high-dose chemotherapy according to institutional
protocols (Table 1). followed bv reinfusion ofthaxxed cell products:
these contained a significantlv lowxer number of CD34- cells for
patients in the test group than patients in the control group (P =
0.0024: Table 4). A total of 5 out of 26 patients in the test group
received the back-up (four patients were target collection failures
with less than 5 x 1IW CD34- cells k-g-1. and the dose of progenitor
cells following selection was considered insufficient for the fifth
one). but are analysed on an intent-to-treat basis. except where
indicated. Figrure 1A and B showxs the cumulatixe probability
(Kaplan-Meier plot) ofachiexving an ANC aboxe 0.5 x 109 1-1 and a
platelet number above 20 x 103 1-1. There was no significant differ-
ence betxeen the t-o groups in time to neutrophil or platelet
recoxerx. Thus. one can be confident that the test arm engrafts
neutrophils and platelets no more than 3 days later than the control
group. Comparison of transfusion requirements. days of antibiotics
use and days of hospitalization did not show anv significant differ-
ence between the control and test groups (Table 6). To eliminate the
possibility that the fixve patients w-ho received a back-up product
(unselected apheresis cell products) in the testgroup may haxe biased
the engraftment data. a subset of the test group including, the 21
patients w-ho received only CD34- cells was analysed. Conclusions
remained unchanged. with no difference between the subset and the
control group in terms of neutrophil or platelet engraftment. There
has been no report oflong-term marro%v dysfunction.
There was no difference betu-een the test group and the control
aroup in the reported incidence of any adverse effect associated
w-ith infusion (reported according to the NCI common toxicity
criteria). The number of infectious episodes w-as identical in both
groups. with 57%c in the control group and 54%e in the test grroup
(Table 7): there was also no difference in the severitv of infectious
episodes: this is supported by comparable antibiotic usage in both
groups. One patient in the control garoup had two episodes of
fungal infections. and one episode of xiral infection: no other
documented opportunistic infection was reported. No infusional
toxicity in the test group was considered to have any relationship
w-ith the use of the cell selection device. Analy1sis of variance to
compare the maximal changes in xital sigrns (respiration. pulse.
temperature. diastolic and syvstolic blood pressure) from before
infusion to after infusion indicated no difference between the tu-o
groups. Serum samples from 11 patients in the test aroup and 11
patients in the control group were checked for the presence of
HAMA and HASA. and were found to be negatixe at baseline and
after transplantation. except for one control patient who Aas posi-
tive for HASA at both time points.
Thirteen of 26 test patients and 13 of 21 control patients haxe
been reported to hax-e relapsed. There has-e been four reported
deaths of patients durinc the first 6 months after transplant. three
in the test group and one in the control group. All had progressive
disease. There have been eight additional deaths reported in the
long-term follow--up. four in each roup. How-ever. it should be
noted that two ofthe relapses and deaths in the test arm occurred in
patients who received back-up unselected products. In order to
better assess the potential effect of positive CD34- cell selection
on relapse and death. we have reanalysed these parameters.
comparing the control group w-ith the test subset. excludinc the
five patients who received unselected back-up PBSCs: this did not
change conclusions. At more than 1 yvear of follow-up for most
patients (median follow-up of 344 days). there is no significant
difference in terms of event-free or oxverall survixal betxeen the
control and test groups. and no pattem suggestive that the test
group is at greater risk.
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DISCUSSION
Here we demonstrate in a prospective randomized study that
selected autologous peripheral blood CD34+ cells support
haematopoietic recovery following high-dose chemotherapy in
patients with poor-prognosis breast cancer, in a similar manner to
unselected mobilized peripheral blood cells. Tumes to neutrophil
and platelet recovery were unaffected by the cell selection in a
group of47 randomized patients who adequately mobilized blood
progenitors as assayed by a number of circulating CD34+ cells
above 20 l-1. There was a trend to increased time to platelet
recovery, an observation similar to a previously published report
(Somlo et al, 1997), but this was not statistically significant, nor
did it translate into more adverse events, or additional require-
ments forplatelettransfusion. These observations were obtained in
a heterogeneous cohort of subjects with poor-prognosis breast
cancer, which reflects, however, the reality of medical practice in
this field, and the lack of standards of care for these patients. In
addition, characteristics ofpatients were equally distributed in the
test group and in the control group, and the study design -
including randomization stratified by participating centre -
allowed for the power to detect a 3-day difference in the time to
neutrophil engraftment.
It is clearthat CD34+ cell selection results in a significant loss of
progenitors. Whereas the study was initially designed so that
patients in the study group and patients in the control group should
have received comparable numbers of CD34+ cells, analysis of
infused cell counts showed that this was not the case. The 26
patients in the study group received a significantly lower number
ofCD34+ cells thandid the 21 patients in the control group, despite
a significantly higher number of aphereses in the former. These
observations reflect both the difficulty during apheresis of
collecting accurately a predefined number ofcells (e.g. more than
2.5 x 106 CD34+ cells kg-' were collected for most control
patients), and the loss ofcells during the separation procedure. It is
interesting that the number of CD34+ cells that were infused in
patients in the study group was below the threshold that we
(Faucher et al, 1996) and others (Bender et al 1992; Bensinger et
al, 1994: Haas et al, 1994; Weaver et al 1995) considered as the
minimal number necessary to ensure the quickest haematological
recovery with unselected PBSCs; on the otherhand, patients in the
control group received on average a number of CD34+ cells that
was close to or above this threshold. The loss of progenitor cells
may explain the delay in platelet recovery observed after trans-
plantation of autologous marrow CD34+ cells, which was previ-
ously demonstrated (Shpall et al, 1997). It is also clear from our
observations that before cell selection one has to use the best
mobilization regimen that is available: because chemotherapy and
haematopoietic growth factors usually result in a better mobiliza-
tion than haematopoietic growth factors alone, the fonner may be
the preferred choice for this kind of treatment strategy; indeed.
there was an excess of patients mobilized with rhG-CSF alone in
the group of patients who failed to meet the mobilization criteria
compared with the group ofrandomized patients. The use of rhG-
CSF alone in a previously published study (Mahe et al, 1996)
resulted in an average number of infused CD34+ cells that was
lower than in the present study, especially for the subset of
myeloma and lymphoma patients who had already received more
than three courses of chemotherapy. Fmally, patients who have a
medical history that predicts a poor ability to mobilize blood pro-
genitors - such as a high number ofprevious chemotherapy cycles
(Bensinger et al, 1994; Haas et al, 1994; Chabannon et al, 1995:
Mahe et al, 1996) - may not be good candidates for cell selection,
unless the yield of CD34+ cells can be improved; although the
difference was not statistically significant, there were more
patients who had received three or more chemotherapy regimens
before inclusion in the group of patients who failed to reach the
threshold of20 circulating CD34+ cells 11-lofblood (non-random-
ized patients).
Tlhe feasibility of CD34+ selection has already been demon-
strated, both for patients with breast cancer and for patients with
other malignancies (Berenson et al, 1991; Brugger et al, 1994b;
Shpall et al, 1994; Gorin et al, 1995; Schiller et al, 1995: Civin et
al, 1996; Lemoli etal, 1996; Maheetal, 1996; Hohaus etal, 1997;
Lopez et al, 1997; Mapara et al, 1997; Marin et al, 1997:
McQuaker et al, 1997; Somlo et al, 1997). The most recent studies
describe the use of apheresis products (Brugger et al, 1994b;
Schiller et al, 1995; Lemoli et al, 1996; Lopez et al, 1997; Mahe et
al, 1996; Hohaus etal, 1997; Maparaetal, 1997; Marinet al. 1997;
Somlo et al, 1997), whereas older publications are based on the
selection ofCD34+ cells from marrow collections (Berenson et al.
1991; Shpall et al, 1994; Gorin et al, 1995; Civin et al, 1996;
Lopez et al, 1997; Shpall et al, 1997). Also, only three publications
(Civin et al, 1996; Hohaus et al. 1997; Mapara et al, 1997) describe
the use ofa biomedical device similar to the one used in this study.
Except for one study with marrow grafts (Shpall et al. 1997) none
of these studies was a randomized study, and haematological
recovery was compared with historical controls. We here provide
additional evidence that CD34+ cells can be safely selected from
apheresis products. Because aphereses contain a higher number of
haematopoietic progenitors than marrow harvests, it is likely that
the consequences of the loss of CD34+ cells during the procedure
will have less influence on autologous haematopoietic recovery.
Tumour purging evaluation was difficult for several reasons.
First, the frequency of positive aphereses is low (equal or lower
than in the bone marrow), even in a population of patients treated
at an advanced stage of their disease; the significance of this low
frequency, and the most appropriate technique to be used for
tumour cell detection in breast cancer remain to be determined
(Mapara et al, 1997). Our observations consistently demonstrate
the possibility of detecting as few as one epithelial tumour cell in
105 to 106 assayed cells, and the percentage of positive aphereses
and patients in our series is consistent with data already published
(Ross et al, 1993; Brugger et al, 1994a; Jones, 1994: Hohaus et al.
1997); only one recent report suggests a much higher frequency of
positive aphereses in advanced breast cancer patients (Mapara et
al, 1997). Second, the clinical consequences oftumour purging are
difficult to assess on such a small number of subjects, and are
unlikely to be apparent in a population ofpatients who mostly had
advanced metastatic disease. In two evaluable patients, detection
of epithelial tumour cells among progenitors, before and after
separation, showed that purging was considerable, albeit partial.
resulting in the reinfusion of a very small number oftumour cells;
this small number is to be compared with the high tumour burden
that characterized all of our patients at the time of high-dose
chemotherapy. The observation that detection of bone marrow
micrometastases using PCR is a strong adverse prognostic factor
(Fields et al, 1996) suggests that eradication of the endogenous
disease remains the most important hurdle in the area ofmetastatic
breast cancer chemotherapy. Tlhe clinical consequences and poten-
tial advantages oftumourpurging will now need to be evaluated in
larger cohorts of patients, and are likely to be more apparent in a
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population of subjects that are transplanted with a lower tumour
burden. such as in the adjuvant setting. However, because the
prognosis ofthis patient population is muchbetterthan forpatients
with metastatic disease. it is likely that this evaluation will require
a large number ofpatients and long-terrn follow-up.
Analysis of the outcome of patients in both groups showed no
difference in terms of relapse rate and event-free survival. As
could be expected from the characteristics of this group of
patients. relapse occurred frequently and early after transplanta-
tion. and progressive disease accounted for all recorded deaths.
This emphasizes the need for better chemotherapy regimens in
patients with poor-prognosis breast cancer (the present study was
however designed to evaluate a new transplant technique. and not
the use of high-dose chemotherapy for the treatment of advanced
or poor-prognosis breast cancer). and again the need to choose a
different population of patients to evaluate the consequences of
tumour purging, once the safety of using selected blood CD34+
cells is definitively established.
In conclusion, we were able to select safely CD34+ cells from
aphereses collected in patients with poor-prognosis breast cancer.
Our randomized study demonstrates that selected CD34+ cells
support haematopoietic recovery after high-dose chemotherapy in
these patients, in a time period similar to that observed in patients
receiving unmanipulated autologous mobilized blood cells.
despite the loss of progenitors during ex vivo cell processing. but
thus at the expense of one additional apheresis. As the demon-
strable clinical benefits associated with positive selection may be
relatively small compared with the many risks associated with
high-dose chemotherapy and progenitor cell reinfusion. it was
important to demonstrate that the risks associated with the use ofa
cell selection device are relatively small. Our observations prepare
the way for future trials designed to evaluate the clinical benefits
associated with CD34+ cell selection.
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